WO1996015132A1 - Improved antiviral prodrugs - Google Patents
Improved antiviral prodrugs Download PDFInfo
- Publication number
- WO1996015132A1 WO1996015132A1 PCT/US1995/014940 US9514940W WO9615132A1 WO 1996015132 A1 WO1996015132 A1 WO 1996015132A1 US 9514940 W US9514940 W US 9514940W WO 9615132 A1 WO9615132 A1 WO 9615132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- octadecyl
- alkyl
- glycero
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
- C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95940014A EP0792275B1 (en) | 1994-11-15 | 1995-11-15 | Improved antiviral prodrugs |
AU41635/96A AU700651B2 (en) | 1994-11-15 | 1995-11-15 | Improved antiviral prodrugs |
CA002205136A CA2205136C (en) | 1994-11-15 | 1995-11-15 | Improved antiviral prodrugs of phosphonoacids |
DE69532642T DE69532642T2 (en) | 1994-11-15 | 1995-11-15 | ANTIVIRAL PRODRUGS |
DK95940014T DK0792275T3 (en) | 1994-11-15 | 1995-11-15 | Enhanced antiviral prodrugs |
JP8516340A JPH10508858A (en) | 1994-11-15 | 1995-11-15 | Improved antiviral prodrug |
AT95940014T ATE260926T1 (en) | 1994-11-15 | 1995-11-15 | ANTIVIRAL PRODRUGS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/340,161 US5696277A (en) | 1994-11-15 | 1994-11-15 | Antiviral prodrugs |
US08/340,161 | 1994-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996015132A1 true WO1996015132A1 (en) | 1996-05-23 |
Family
ID=23332146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/014940 WO1996015132A1 (en) | 1994-11-15 | 1995-11-15 | Improved antiviral prodrugs |
Country Status (11)
Country | Link |
---|---|
US (2) | US5696277A (en) |
EP (1) | EP0792275B1 (en) |
JP (1) | JPH10508858A (en) |
AT (1) | ATE260926T1 (en) |
AU (1) | AU700651B2 (en) |
CA (1) | CA2205136C (en) |
DE (1) | DE69532642T2 (en) |
DK (1) | DK0792275T3 (en) |
ES (1) | ES2217287T3 (en) |
PT (1) | PT792275E (en) |
WO (1) | WO1996015132A1 (en) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022613A1 (en) * | 1995-12-15 | 1997-06-26 | Boehringer Mannheim Gmbh | Phospholipid derivatives of phosphono-carboxylic acids, the production of said derivatives and the use of said derivatives as antiviral medicaments |
WO1998016537A1 (en) * | 1996-10-11 | 1998-04-23 | Astra Aktiebolag (Publ) | Novel compounds |
WO1998025938A1 (en) * | 1996-12-13 | 1998-06-18 | Astra Aktiebolag (Publ) | Novel compounds |
WO1999051613A1 (en) * | 1998-04-03 | 1999-10-14 | Medivir Ab | Prodrugs of phosphorous-containing pharmaceuticals |
US6245749B1 (en) | 1994-10-07 | 2001-06-12 | Emory University | Nucleosides with anti-hepatitis B virus activity |
US6395716B1 (en) | 1998-08-10 | 2002-05-28 | Novirio Pharmaceuticals Limited | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US6670342B2 (en) | 2000-03-29 | 2003-12-30 | Georgetown University | Method of treating hepatitis delta virus infection |
WO2004002999A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
EP1382343A1 (en) | 1998-11-02 | 2004-01-21 | Triangle Pharmaceuticals Inc. | Combination therapy to treat hepatitis B virus |
US6686462B2 (en) | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
WO2005003147A2 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US7186700B2 (en) | 2002-09-13 | 2007-03-06 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
US7192936B2 (en) | 2002-06-28 | 2007-03-20 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7323451B2 (en) | 2002-08-06 | 2008-01-29 | Idenix Pharmaceuticals, Inc. | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
US7439351B2 (en) | 1993-09-10 | 2008-10-21 | The Uab Research Foundation | 2′ or 3′ -deoxy and 2′, 3′-dideoxy-β-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents |
US7625875B2 (en) | 2002-06-28 | 2009-12-01 | Idenix Pharmaceuticals, Inc. | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
EP2251015A1 (en) | 2000-10-18 | 2010-11-17 | Pharmasset, Inc. | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
EP2319856A1 (en) | 2000-05-23 | 2011-05-11 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus |
EP2390257A1 (en) | 1998-02-25 | 2011-11-30 | Emory University | 2'-fluoronucleosides |
EP2574341A1 (en) | 2004-03-29 | 2013-04-03 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
US8492539B2 (en) | 2004-09-14 | 2013-07-23 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US8569478B2 (en) | 2005-09-26 | 2013-10-29 | Gilead Pharmasset Llc | Modified 4′-nucleosides as antiviral agents |
US8580765B2 (en) | 2007-03-30 | 2013-11-12 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8629263B2 (en) | 2009-05-20 | 2014-01-14 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8742101B2 (en) | 2003-07-25 | 2014-06-03 | Idenix Pharmaceuticals, Inc. | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
US9284342B2 (en) | 2009-05-20 | 2016-03-15 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EP3042660A2 (en) | 2008-04-15 | 2016-07-13 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
WO2018023054A1 (en) * | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
US9968628B2 (en) | 2000-05-26 | 2018-05-15 | Idenix Pharmaceuticals Llc | Methods and compositions for treating flaviviruses and pestiviruses |
US11116783B2 (en) | 2013-08-27 | 2021-09-14 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696277A (en) * | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
US20030229040A1 (en) * | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
US6559129B1 (en) * | 1997-03-21 | 2003-05-06 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
US7262173B2 (en) * | 1997-03-21 | 2007-08-28 | Georgetown University | Chemosensitizing with liposomes containing oligonucleotides |
US6444837B1 (en) * | 1998-07-13 | 2002-09-03 | University Of Southern California | Synthesis and antiviral activity of a series of pyrophosphate analogs |
MXPA02006491A (en) * | 1999-12-29 | 2002-11-29 | Univ California | Treatment of drugresistant human immunodeficiency virus infection. |
US20030114385A1 (en) * | 2001-04-27 | 2003-06-19 | Cathers Brian E. | Viral enzyme activated prototoxophores and use of same to treat viral infections |
CN101172993A (en) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US20070207973A1 (en) * | 2002-09-24 | 2007-09-06 | Koronis Pharmaceuticals, Incorporated | 1,3,5-Triazines for Treatment of Viral Diseases |
US7772197B2 (en) * | 2002-09-24 | 2010-08-10 | 1,3,5-Triazines for Treatment of Viral Diseases | 1,3,5-triazines for treatment of viral diseases |
US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
AU2003300434A1 (en) * | 2002-12-23 | 2004-07-22 | Idenix (Cayman) Limited | Process for the production of 3'-nucleoside prodrugs |
US20070211471A1 (en) * | 2003-10-27 | 2007-09-13 | Wimberly Randal L | Dual Reflector System |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
EP1912643A2 (en) * | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
TW200628161A (en) * | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
JP4516863B2 (en) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | Speech synthesis apparatus, speech synthesis method and program |
EP1868628B1 (en) * | 2005-04-08 | 2014-06-11 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
EP2842559A3 (en) | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
EP1976382B1 (en) | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
US7950880B2 (en) * | 2006-10-18 | 2011-05-31 | Kennametal Inc. | Spiral flute tap |
WO2009094190A2 (en) | 2008-01-25 | 2009-07-30 | Chimerix, Inc. | Methods of treating viral infections |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
EP3216789A1 (en) | 2010-02-12 | 2017-09-13 | Chimerix, Inc. | Methods of treating viral infection |
AU2011248620B2 (en) | 2010-04-26 | 2015-11-26 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
WO2014143643A1 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California, A California Corporation | Acyclic nucleoside phosphonate diesters |
KR102589658B1 (en) | 2014-09-15 | 2023-10-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Nucleotide analogs |
US10377782B2 (en) | 2015-09-15 | 2019-08-13 | The Regents Of The University Of California | Nucleotide analogs |
EP3813839A4 (en) * | 2018-06-26 | 2022-07-20 | TSRL, Inc. | Metabolically stable prodrugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7607496L (en) * | 1976-07-01 | 1978-01-02 | Astra Laekemedel Ab | METHOD FOR FIGHTING VIRUS INFECTIONS |
CA1140049A (en) * | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
US5072032A (en) * | 1989-06-21 | 1991-12-10 | Mckenna Charles E | Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
EP0673256A4 (en) * | 1992-12-09 | 1997-01-29 | Indiana University Foundation | Suppression of myeloid cells. |
US5696277A (en) * | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
-
1994
- 1994-11-15 US US08/340,161 patent/US5696277A/en not_active Expired - Lifetime
-
1995
- 1995-11-15 PT PT95940014T patent/PT792275E/en unknown
- 1995-11-15 JP JP8516340A patent/JPH10508858A/en active Pending
- 1995-11-15 EP EP95940014A patent/EP0792275B1/en not_active Expired - Lifetime
- 1995-11-15 CA CA002205136A patent/CA2205136C/en not_active Expired - Fee Related
- 1995-11-15 ES ES95940014T patent/ES2217287T3/en not_active Expired - Lifetime
- 1995-11-15 AT AT95940014T patent/ATE260926T1/en not_active IP Right Cessation
- 1995-11-15 DE DE69532642T patent/DE69532642T2/en not_active Expired - Lifetime
- 1995-11-15 WO PCT/US1995/014940 patent/WO1996015132A1/en active IP Right Grant
- 1995-11-15 DK DK95940014T patent/DK0792275T3/en active
- 1995-11-15 AU AU41635/96A patent/AU700651B2/en not_active Ceased
-
1997
- 1997-12-08 US US08/986,881 patent/US6002029A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US7439351B2 (en) | 1993-09-10 | 2008-10-21 | The Uab Research Foundation | 2′ or 3′ -deoxy and 2′, 3′-dideoxy-β-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents |
US6245749B1 (en) | 1994-10-07 | 2001-06-12 | Emory University | Nucleosides with anti-hepatitis B virus activity |
WO1997022613A1 (en) * | 1995-12-15 | 1997-06-26 | Boehringer Mannheim Gmbh | Phospholipid derivatives of phosphono-carboxylic acids, the production of said derivatives and the use of said derivatives as antiviral medicaments |
CN1085672C (en) * | 1995-12-15 | 2002-05-29 | 罗赫诊断器材股份有限公司 | Phospholipid derivatives of phosphono-carboxylic acids, prodn. and use as antiviral |
WO1998016537A1 (en) * | 1996-10-11 | 1998-04-23 | Astra Aktiebolag (Publ) | Novel compounds |
WO1998025938A1 (en) * | 1996-12-13 | 1998-06-18 | Astra Aktiebolag (Publ) | Novel compounds |
US6686462B2 (en) | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
US6974802B2 (en) | 1998-02-13 | 2005-12-13 | Medivir Ab | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine |
US7071173B2 (en) | 1998-02-13 | 2006-07-04 | Medivir Ab | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine |
EP2392580A1 (en) | 1998-02-25 | 2011-12-07 | Emory University | 2'-fluoronucleosides |
EP2390257A1 (en) | 1998-02-25 | 2011-11-30 | Emory University | 2'-fluoronucleosides |
WO1999051613A1 (en) * | 1998-04-03 | 1999-10-14 | Medivir Ab | Prodrugs of phosphorous-containing pharmaceuticals |
EP2415776A1 (en) | 1998-08-10 | 2012-02-08 | IDENIX Pharmaceuticals, Inc. | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B |
US9290533B2 (en) | 1998-08-10 | 2016-03-22 | Novartis Ag | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6395716B1 (en) | 1998-08-10 | 2002-05-28 | Novirio Pharmaceuticals Limited | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6566344B1 (en) | 1998-08-10 | 2003-05-20 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6946450B2 (en) | 1998-08-10 | 2005-09-20 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6569837B1 (en) | 1998-08-10 | 2003-05-27 | Idenix Pharmaceuticals Inc. | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
US7795238B2 (en) | 1998-08-10 | 2010-09-14 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US7304043B2 (en) | 1998-08-10 | 2007-12-04 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
EP1382343A1 (en) | 1998-11-02 | 2004-01-21 | Triangle Pharmaceuticals Inc. | Combination therapy to treat hepatitis B virus |
US6670342B2 (en) | 2000-03-29 | 2003-12-30 | Georgetown University | Method of treating hepatitis delta virus infection |
US7511027B2 (en) | 2000-03-29 | 2009-03-31 | Georgetown University | Method of treating hepatitis delta virus infection |
US10758557B2 (en) | 2000-05-23 | 2020-09-01 | Idenix Pharmaceuticals Llc | Methods and compositions for treating hepatitis C virus |
US10363265B2 (en) | 2000-05-23 | 2019-07-30 | Idenix Pharmaceuticals Llc | Methods and compositions for treating hepatitis C virus |
EP2319856A1 (en) | 2000-05-23 | 2011-05-11 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus |
US9968628B2 (en) | 2000-05-26 | 2018-05-15 | Idenix Pharmaceuticals Llc | Methods and compositions for treating flaviviruses and pestiviruses |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US7585851B2 (en) | 2000-06-15 | 2009-09-08 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
EP2251015A1 (en) | 2000-10-18 | 2010-11-17 | Pharmasset, Inc. | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
US7365057B2 (en) | 2002-06-28 | 2008-04-29 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flavivridae infections |
EP2799442A1 (en) | 2002-06-28 | 2014-11-05 | IDENIX Pharmaceuticals, Inc. | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
US7662798B2 (en) | 2002-06-28 | 2010-02-16 | Idenix Pharmaceuticals, Inc. | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7625875B2 (en) | 2002-06-28 | 2009-12-01 | Idenix Pharmaceuticals, Inc. | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7192936B2 (en) | 2002-06-28 | 2007-03-20 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7384924B2 (en) | 2002-06-28 | 2008-06-10 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7547704B2 (en) | 2002-06-28 | 2009-06-16 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
WO2004002999A2 (en) | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
EP2332952A1 (en) | 2002-06-28 | 2011-06-15 | IDENIX Pharmaceuticals, Inc. | Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections |
US7635689B2 (en) | 2002-06-28 | 2009-12-22 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7589079B2 (en) | 2002-08-06 | 2009-09-15 | Novartis Ag | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
US7323451B2 (en) | 2002-08-06 | 2008-01-29 | Idenix Pharmaceuticals, Inc. | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
US7858594B2 (en) | 2002-08-06 | 2010-12-28 | Novartis Pharma Ag | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
US8158606B2 (en) | 2002-09-13 | 2012-04-17 | Novartis, Ag | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
US7928086B2 (en) | 2002-09-13 | 2011-04-19 | Novartis Ag | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
US7186700B2 (en) | 2002-09-13 | 2007-03-06 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
US10525072B2 (en) | 2002-11-15 | 2020-01-07 | Idenix Pharmaceuticals Llc | 2′-branched nucleosides and flaviviridae mutation |
US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
EP2604620A1 (en) | 2003-05-30 | 2013-06-19 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
EP2345658A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
EP2345659A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
EP2345661A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US10287311B2 (en) | 2003-05-30 | 2019-05-14 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
EP4032897A1 (en) | 2003-05-30 | 2022-07-27 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
EP3521297A1 (en) | 2003-05-30 | 2019-08-07 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
WO2005003147A2 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US8742101B2 (en) | 2003-07-25 | 2014-06-03 | Idenix Pharmaceuticals, Inc. | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
US9186369B2 (en) | 2003-07-25 | 2015-11-17 | Idenix Pharmaceuticals, Llc | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
EP2574341A1 (en) | 2004-03-29 | 2013-04-03 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
US10577359B2 (en) | 2004-09-14 | 2020-03-03 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US8492539B2 (en) | 2004-09-14 | 2013-07-23 | Gilead Pharmasset Llc | Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
EP3159351A2 (en) | 2005-09-26 | 2017-04-26 | Gilead Pharmasset LLC | Modified 3'-azido-4'-ethynyl-nucleosides as antiviral agents |
US8569478B2 (en) | 2005-09-26 | 2013-10-29 | Gilead Pharmasset Llc | Modified 4′-nucleosides as antiviral agents |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
US9585906B2 (en) | 2007-03-30 | 2017-03-07 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US10183037B2 (en) | 2007-03-30 | 2019-01-22 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8580765B2 (en) | 2007-03-30 | 2013-11-12 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9085573B2 (en) | 2007-03-30 | 2015-07-21 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8906880B2 (en) | 2007-03-30 | 2014-12-09 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US8735372B2 (en) | 2007-03-30 | 2014-05-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US11642361B2 (en) | 2007-03-30 | 2023-05-09 | Gilead Sciences, Inc. | Nucleoside phosphoramidate prodrugs |
US8957046B2 (en) | 2007-03-30 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
EP3042660A2 (en) | 2008-04-15 | 2016-07-13 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8957045B2 (en) | 2008-12-23 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9284342B2 (en) | 2009-05-20 | 2016-03-15 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9206217B2 (en) | 2009-05-20 | 2015-12-08 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9637512B2 (en) | 2009-05-20 | 2017-05-02 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8642756B2 (en) | 2009-05-20 | 2014-02-04 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8633309B2 (en) | 2009-05-20 | 2014-01-21 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8629263B2 (en) | 2009-05-20 | 2014-01-14 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9394331B2 (en) | 2010-11-30 | 2016-07-19 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9549941B2 (en) | 2011-11-29 | 2017-01-24 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
EP3750544A2 (en) | 2011-11-30 | 2020-12-16 | Emory University | Jak inhibitors for use in the prevention or treatment of viral infection |
WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
US11116783B2 (en) | 2013-08-27 | 2021-09-14 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US11707479B2 (en) | 2013-08-27 | 2023-07-25 | Gilead Sciences, Inc. | Combination formulation of two antiviral compounds |
WO2018023054A1 (en) * | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
US11033600B2 (en) | 2016-07-28 | 2021-06-15 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
Also Published As
Publication number | Publication date |
---|---|
PT792275E (en) | 2004-09-30 |
EP0792275A1 (en) | 1997-09-03 |
US5696277A (en) | 1997-12-09 |
DK0792275T3 (en) | 2004-07-05 |
CA2205136A1 (en) | 1996-05-23 |
CA2205136C (en) | 2008-01-22 |
ES2217287T3 (en) | 2004-11-01 |
AU4163596A (en) | 1996-06-06 |
AU700651B2 (en) | 1999-01-14 |
JPH10508858A (en) | 1998-09-02 |
DE69532642D1 (en) | 2004-04-08 |
DE69532642T2 (en) | 2005-06-30 |
ATE260926T1 (en) | 2004-03-15 |
EP0792275A4 (en) | 1998-02-25 |
US6002029A (en) | 1999-12-14 |
EP0792275B1 (en) | 2004-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0792275B1 (en) | Improved antiviral prodrugs | |
AU711774B2 (en) | Prodrugs of pharmaceuticals with improved bioavailability | |
US6030960A (en) | Method of treating hepatitis virus infections | |
CA2149753C (en) | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use | |
US5744461A (en) | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use | |
EP0781138B1 (en) | Lipid analogs for treating viral infections | |
JP4782365B2 (en) | Compositions and methods for dual targeting of viral infections and cancer cells | |
JPH05507929A (en) | Ether lipid-nucleoside covalent conjugate | |
JP5031162B2 (en) | Compositions and methods for dual targeting viral infection and targeting cancer cells | |
AU714236B2 (en) | New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents | |
AU714922B2 (en) | Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents | |
EP0080305A1 (en) | Antiviral 2'-deoxyuridines, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2205136 Country of ref document: CA Ref country code: CA Ref document number: 2205136 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995940014 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995940014 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995940014 Country of ref document: EP |